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Aim
To provide an educational update on structural imaging
appearances of neuroendocrine tumours (NET), in the
age of molecular imaging.
PET/CT with Ga-68 DOTA-TATE and F-18 fluoro-
deoxyglucose (FDG) is providing new understanding of
neuroendocrine tumours including patterns and heteroge-
neity of disease. This is also providing new insights of
structural imaging findings including CT and MRI. It is
also important to be aware of the limitations of PET/CT
imaging, and we outline indications where structural
imaging has a high impact for patient management. These
changing paradigms are translating to revised imaging
protocols in our institution that are enabling personalised
medicine with appropriate selection of management for an
individual patient. It is also allowing us to understand the
structural imaging appearances of heterogeneity within the
same tumour type. A range of new targeted therapies
including peptide receptor radionuclide therapy (PRRT)
are now available to treat patients with non-resectable
metastatic NET. New patterns of response are emerging
which are important to recognise, including cystic necrosis
which may initially masquerade as progressive disease due
to enlargement.
We have a large population of patients with neuroen-
docrine tumours at Peter MacCallum Cancer Institute,
providing wide experience of this spectrum of imaging
findings across various subtypes of NET. We present a
pictorial review of our experience.
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